IRMD
IRADIMED CORP
Next earnings Jul 30, 2026 · consensus $0.43 EPS, $20.8M rev
Last earnings +4.4% on 2026-05-01
$93.96
▲ +0.10%$93.96▲ +60.13%
over 1Y
L $55.42EODHDH $104.87
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.1%
1W+2.5%
1M+2.3%
3M-3.3%
YTD-1.2%
1Y+60.1%
Buy
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Revenue grew 14.4% YoY; but rich valuation (P/E 52.4).
Revenue (FY2025) $83.8M · FY2025
The read
The fundamentals carry the rating, but the price is rich (~31% above our fair-value estimate) — a quality-at-a-price call. The case rests on the business, not the entry; patient buyers may wait for a pullback.
IRADIMED CORP shows $83.8M in FY2025 revenue (+14.4% YoY), a 26.8% net margin, and 23.8% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $41.8M | $53.3M | $65.6M | $73.2M | $83.8M |
| Gross profit | $32.0M | $41.3M | $50.2M | $56.4M | $64.3M |
| Operating income | $9.82M | $15.6M | $20.0M | $22.0M | $26.1M |
| Net income | $9.33M | $12.8M | $17.2M | $19.2M | $22.5M |
| Diluted EPS | $0.74 | $1.02 | $1.35 | $1.50 | $1.75 |
| Net margin | 22.3% | 24.1% | 26.2% | 26.3% | 26.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$1.15B
EV / EBITDA42.1
EV / Sales13.7
EV / FCF66.9
P / FCF69.9
PEG (trailing)3.18
Earnings yield1.9%
FCF yield1.4%
Quality & risk
ROIC (est.)21.8%
Free cash flow$17.2M
Total debt—
Net cash$51.2M
Altman Z-Score54.07 safe
Piotroski F-Score5/8
Capital returns
Buyback yield0.2%
Dividend yield (est.)1.3%
Shareholder yield1.4%
Shares Δ YoY+0.5%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-242026-06-24open ↗4Period ending 2026-06-202026-06-23open ↗4Period ending 2026-06-042026-06-04open ↗144Filing2026-06-04open ↗4Period ending 2026-06-012026-06-02open ↗4Period ending 2026-05-262026-05-28open ↗4Period ending 2026-05-182026-05-20open ↗SCHEDULE 13G/AFiling2026-05-14open ↗4Period ending 2026-05-112026-05-13open ↗4Period ending 2026-05-042026-05-06open ↗10-QPeriod ending 2026-03-312026-05-01open ↗8-KPeriod ending 2026-05-012026-05-01open ↗
Frequently asked
- Is IRADIMED CORP (IRMD) a buy?
- IRMD currently carries a Buy rating with 4/5 conviction, derived from its latest SEC filings. Revenue grew 14.4% YoY; but rich valuation (P/E 52.4).
- What is IRMD's fair value?
- A Modified-Graham model based on IRMD's SEC fundamentals estimates a fair value of about $64.65. It is an estimate from reported earnings, not a price target.
- Is IRMD overvalued or undervalued?
- Against a Modified-Graham fair-value estimate, IRMD currently appears overvalued relative to its SEC-grounded earnings power.
- What is IRADIMED CORP's quality score?
- IRMD scores 74.33333333333333/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001325618, latest 10-Q filed 2026-05-01) · EODHD · as of 6/22/2026, 9:48:55 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.